Project Grant R03AG083470

Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $328K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $778,499 to the University of Texas Health Science Center at Houston to develop novel machine learning models to reveal and stratify heterogeneous subpopulations of Alzheimer's disease (AD) patients based on risk and progression patterns. The goal is to transform these subpopulations into potentially targetable groups to enable focused clinical trials, support future therapeutic development, and...
This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development and application of statistical methods to improve scientific inferences in Alzheimer's disease (AD) research. The $455,274 award, effective May 15, 2025, focuses on three key aims: Developing methods to handle age-specific prevalent cases in AD case-control studies and address survivor bias. Developing regression techniques to analyze age at biomarker positivity and time to onset...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $129,330 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a multi-modal information framework that leverages decades-long in vivo and digital biomarkers to profile the inter-individual heterogeneity of Alzheimer's disease and related dementias (ADRD) and build a risk prediction model of time-to-diagnosis using machine learning and time series...
The federal Project Grant award of $5,262,301 from the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) program supports the "Triangulation of Innovative Methods to END AD (TIME-AD)" project. The project aims to strengthen causal inference in observational data to better understand Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) risk factors. The project includes four research projects that will use innovative methods like doubly robust...
The National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) Federal Grant Program, awarded a $366,648 Project Grant to New York University (NYU) on May 15, 2025. The grant supports the development of statistical methods to enhance the accuracy of estimation and prediction in Alzheimer's disease (AD) progression based on longitudinal cohort studies. Key focus areas include: Enabling the use of clinically meaningful time origins in estimating time-to-event endpoints for AD...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop an interpretable deep learning framework called the Interpretable Generative Transcriptional Program (IGTP) to investigate the genes and pathways associated with cognitive resilience in Alzheimer's disease (AD) and identify potential synergistic perturbations that may enhance cognitive resilience. The $897,000 award, with a project period from August 1, 2024 to April 30, 2026, will fund...
This federal Project Grant award of $307,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a single, highly powered study to identify memory processes that are most sensitive to the asymptomatic, preclinical stage of Alzheimer's disease (AD) pathology. The study combines a continuous report item-location associative memory task with advanced behavioral and neural modeling to estimate subtle changes in memory precision that may differentiate healthy...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research program provides $622,401 to the University of Southern California (USC) to conduct research on causal modeling of brain biomarker changes related to Alzheimer's disease and related dementias (ADRD). The project aims to: 1) fit novel deep learning models to predict cerebrospinal fluid and PET-derived amyloid load from diffusion MRI data in symptomatic vs. pre-symptomatic individuals; 2)...

TIME-DYNAMIC TREE-BASED METHODS FOR PERSONALIZED ALZHEIMER'S DISEASE PREDICTION - PROJECT SUMMARY (ABSTRACT) THIS TWO-YEAR GRANT PROPOSAL RESPONDS TO PAR-23-179, AND ITS LONG-TERM GOAL IS TO ADVANCE THE UNDERSTANDING OF BIOMARKER IN RELATION TO PRECLINICAL ALZHEIMER'S DISEASE (AD). THIS PROPOSAL SEEKS TO LEVERAGE INTERPRETABLE AND FLEXIBLE TREE-BASED METHODS, CLINICALLY AND BIOLOGICALLY INFORMED TREE DECISION RULES, LONGITUDINAL BIOMARKERS, AND RISK AND PROTECTIVE FACTORS, TO DEVELOP NOVEL STATISTICAL METHODS AND CONSTRUCT TREE-BASED ALGORITHMS. THE NOVEL METHODS AND TREE-BASED ALGORITHMS WILL HELP IDENTIFY TIME-DYNAMIC AND PERSONALIZED BIOMARKER SUBGROUPS AT HIGH RISK FOR COGNITIVE DECLINE DUE TO AD AND PREDICT PROGRESSION RISKS. AD IS A DEVASTATING DISEASE AFFECTING OVER 6 MILLION PEOPLE IN THE U.S. AND HAS BURDENED THE U.S. HEALTHCARE SYSTEM AND CAREGIVERS WITH INCREASES. IMPORTANTLY, EVIDENCE SUGGESTS THAT THE PATHOPHYSIOLOGICAL PROCESS BEGINS MANY YEARS, IF NOT DECADES, BEFORE THE DIAGNOSIS OF AD DEMENTIA, AND RECENT FINDINGS DEMONSTRATE THAT BIOMARKER DETERIORATION STARTS MANY YEARS BEFORE COGNITIVE DECLINE DUE TO AD. IDENTIFYING HIGH-RISK SUBGROUPS BASED ON BIOMARKER INFORMATION WILL EXPAND THE WINDOW OF OPPORTUNITY DURING WHICH THERAPEUTIC INTERVENTION MAY HAVE THE GREATEST POTENTIAL FOR SUCCESS. TREE-BASED METHODS APPEAR WELL-SUITED FOR PRODUCING CLINICALLY APPLICABLE DECISION RULES THAT LEVERAGE COMPLICATED INTERACTIONS BETWEEN DIFFERENT BIOMARKERS, AND BETWEEN BIOMARKERS AND RISK FACTORS. BUT EXISTING TREE-BASED METHODS ARE LIMITED IN CLINICAL RELEVANCE, BIOLOGICAL INTERPRETABILITY, AND STATISTICAL INFERENCE, AND NOVEL METHODS ARE NEEDED. MEANWHILE, THE CONSORTIUM OF MULTIPLE LONGITUDINAL FOLLOW-UP STUDIES PRESENTS NEW OPPORTUNITIES AND CHALLENGES. THE PRECLINICAL AD CONSORTIUM (PAC) DATA COMPRISES FIVE STUDIES THAT HAVE BEEN COLLECTING LONGITUDINAL CLINICAL, COGNITIVE, BIOMARKER, AND GENETIC DATA FROM INDIVIDUALS WHO WERE COGNITIVELY NORMAL WHEN FIRST ENROLLED AND FOLLOWED FOR MANY YEARS. THE LARGE SAMPLE SIZE AND THE BREADTH OF THE MERGED AND HARMONIZED DATA CREATE OPPORTUNITIES FOR MORE PRECISE AND PERSONALIZED CLASSIFICATION AND RISK PREDICTION, BASED ON LONGITUDINAL BIOMARKERS AND RISK AND PROTECTIVE FACTORS. THESE OPPORTUNITIES ALSO CREATE CHALLENGES FOR METHOD DEVELOPMENT TO BE TIME-DYNAMIC AND PERSONALIZED. PROJECTS SUPPORTED BY THIS PROPOSAL WILL SEEK TO DEVELOP NOVEL TREE-BASED STATISTICAL METHODS FOR SUBGROUP IDENTIFICATION AND RISK PREDICTION FOR COGNITIVE DECLINE DUE TO AD, AND CONSTRUCT CLASSIFICATION AND PREDICTION ALGORITHMS USING THE PAC DATA. OUR RESEARCH TEAM WILL PURSUE THESE GOALS THROUGH TWO SPECIFIC AIMS: (1) ESTABLISH A TIME-DYNAMIC AND PERSONALIZED STATISTICAL CLASSIFICATION AND PREDICTION FRAMEWORK USING TREE-BASED METHODS; AND (2) LEVERAGE THE PAC DATA TO CONSTRUCT CLASSIFICATION AND PREDICTION ALGORITHMS FOR ONSET OF AD- RELATED CLINICAL SYMPTOMS. SUCCESSFUL COMPLETION OF THESE AIMS WILL PRODUCE NOVEL TREE-BASED METHODOLOGIES AND GENERATE TREE-BASED CLASSIFICATION AND PREDICTION ALGORITHMS THAT PREDICT ONSET OF AD-RELATED SYMPTOMS.

Posted 6/17/24, 12:00 AM